KM
KMTS.US Kestra Medical Technologies, Ltd. Common Stock
- Market cap
- USD 1.71B
- P/E
- -
- P/B
- 7.68x
- ROE
- -79.3%
- Dividend yield
- 0.02%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jul 2026.
Is KMTS.US undervalued?
Graham numberThe Graham number of Kestra Medical Technologies, Ltd. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kestra Medical Technologies, Ltd. Common Stock fundamental analysis
No fundamental analysis for Kestra Medical Technologies, Ltd. Common Stock yet.
Kestra Medical Technologies, Ltd. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kestra Medical Technologies, Ltd. Common Stock
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. The company also develops and commercializes Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable…
Full company profileKestra Medical Technologies, Ltd. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kestra Medical Technologies, Ltd. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 7.63M | 27.8M | 59.8M | 95.1M | 124M |
| Gross Profit | - | - | -10.7M | 362K | 24.2M | 48.9M | 70.0M |
| Operating Income | -29.3M | -32.7M | -80.4M | -85.1M | -106M | -135M | -151M |
| EBITDA | -28.8M | -32.3M | -73.7M | -76.3M | -98.0M | -137M | -140M |
| Net Income | -29.5M | -34.1M | -84.2M | -94.1M | -114M | -132M | -176M |
| EPS | -0.59 | -1.71 | -1.70 | -1.90 | -2.30 | -2.25 | -3.01 |
| Balance Sheet | |||||||
| Total Assets | 7.87M | 30.5M | 38.7M | 45.9M | 296M | 358M | 347M |
| Total Liabilities | 4.02M | 28.8M | 156M | 255M | 90.3M | 98.8M | 125M |
| Shareholders' Equity | 3.86M | 1.77M | -118M | -209M | 205M | 260M | 222M |
| Cash & Short-term Investments | 5.76M | 24.3M | 14.8M | 8.25M | 238M | 196M | 199M |
| Total Debt | 452K | 22.8M | 39.1M | 45.2M | 44.3M | 46.8M | 76.4M |
| Cash Flow | |||||||
| Operating Cash Flow | -30.3M | -29.9M | -69.6M | -72.2M | -77.6M | -81.7M | -129M |
| Capital Expenditure | 232K | 336K | 15.5M | 12.5M | 23.6M | 34.9M | 33.3M |
| Free Cash Flow | -30.5M | -30.2M | -85.1M | -84.7M | -101M | -117M | -163M |
| Ratios | |||||||
| ROE | -764.0% | -1,931.0% | - | - | -55.4% | -50.7% | -79.3% |
| ROA | -374.3% | -111.7% | -217.9% | -204.8% | -38.5% | -36.7% | -50.8% |
| Net Profit Margin | - | - | -1,104.0% | -338.4% | -190.3% | -138.4% | -142.3% |
| Debt to Equity | 0.12x | 12.94x | - | - | 0.22x | 0.18x | 0.34x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kestra Medical Technologies, Ltd. Common Stock dividends
- Dividend yield
- 0.02%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | USD 323K | 0.01 | - |
| 2025 | USD 1.65M | 0.03 | - |
| 2024 | USD 799K | 0.02 | - |
| 2023 | USD 671K | 0.01 | - |
| 2021 | USD 187K | 0.01 | - |
| 2020 | USD 183K | 0.00 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Kestra Medical Technologies, Ltd. Common Stock
- Insiders 5.81%
- Institutions 94.19%
- Public & others 0.00%
- Shares outstanding 59.6M
- Free float 33.7M
Top funds holding KMTS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| T. Rowe Price New Horizons | 2.58M | 4.33% | +5.55% | Sep 2026 |
| Eventide Healthcare & Life Sciences I | 1.37M | 2.30% | 0.00% | Jun 2026 |
| Fidelity Select Medical Tech and Devcs | 1.04M | 1.75% | +4.00% | Sep 2026 |
| Fidelity Select Health Care | 1.00M | 1.68% | +0.02% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 927K | 1.56% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 678K | 1.14% | 0.00% | Oct 2026 |
| Franklin Small Cap Growth Adv | 671K | 1.13% | -13.40% | Sep 2026 |
| Fidelity Stock Selector Small Cap | 634K | 1.06% | 0.00% | Aug 2026 |
| Federated Hermes Kaufmann Small Cap A | 615K | 1.03% | +17.14% | Sep 2026 |
| AB Small Cap Growth A | 601K | 1.01% | -1.73% | Sep 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 509K | 0.85% | 0.00% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 500K | 0.84% | 0.00% | Sep 2026 |
| Fidelity Advisor Health Care I | 500K | 0.84% | +5.26% | Sep 2026 |
| Fidelity Blue Chip Growth | 433K | 0.73% | 0.00% | Sep 2026 |
| Principal SmallCap Growth I Instl | 433K | 0.73% | -0.06% | Sep 2026 |
| Fidelity Series Small Cap Opps | 383K | 0.64% | -2.52% | Aug 2026 |
| Osterweis Opportunity Fund | 336K | 0.56% | +9.10% | Sep 2026 |
| Schroder US Smaller Companies Acc | 326K | 0.55% | +1.61% | Sep 2026 |
| Brown Advisory Small-Cap Growth Inv | 295K | 0.50% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 293K | 0.49% | 0.00% | Aug 2026 |
Top institutions holding KMTS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Bain Capital Investors LLC | 25.2M | 42.26% | 0.00% | Jun 2026 |
| FMR Inc | 5.52M | 9.27% | -3.45% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 4.97M | 8.34% | -16.75% | Jun 2026 |
| Andera Partners | 2.73M | 4.58% | +1.24% | Jun 2026 |
| Yu Fan | 2.28M | 3.83% | 0.00% | Jun 2026 |
| Brown Advisory Holdings Inc | 1.91M | 3.21% | +10.75% | Jun 2026 |
| BlackRock Inc | 1.87M | 3.13% | +10.43% | Jun 2026 |
| AllianceBernstein L.P. | 1.48M | 2.48% | +11.94% | Jun 2026 |
| Eventide Asset Management, LLC | 1.45M | 2.43% | +0.06% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.18M | 1.97% | -3.06% | Jun 2026 |
| Franklin Templeton Inc | 1.12M | 1.89% | -9.62% | Jun 2026 |
| Omega Fund Management LLC | 1.02M | 1.72% | 0.00% | Jun 2026 |
| Hood River Capital Management LLC | 754K | 1.27% | +14.89% | Jun 2026 |
| State Street Corp | 748K | 1.26% | +11.41% | Jun 2026 |
| Geode Capital Management, LLC | 647K | 1.09% | +12.80% | Jun 2026 |
| Point72 Asset Management, L.P. | 527K | 0.88% | 0.00% | Jun 2026 |
| Federated Hermes Inc | 525K | 0.88% | 0.00% | Jun 2026 |
| Driehaus Capital Management LLC | 449K | 0.75% | +0.29% | Jun 2026 |
| Next Century Growth Investors LLC | 444K | 0.75% | -3.15% | Sep 2026 |
| UBS Group AG | 326K | 0.55% | -6.82% | Jun 2026 |
Kestra Medical Technologies, Ltd. Common Stock company profile
- Company name
- Kestra Medical Technologies, Ltd. Common Stock
- Ticker
- KMTS.US
- ISIN
- BMG524411052
- Exchange
- USA Stocks
- Listed since
- Mar 6, 2025
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 443
- Fiscal year end
- April
- Address
- 3933 Lake Washington Blvd NE, Kirkland, WA, United States, 98033
- Phone
- 425 279 8002
- Website
- kestramedical.com
About Kestra Medical Technologies, Ltd. Common Stock
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. The company also develops and commercializes Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable periods of recovery. Its platform provides ASSURE Wearable Cardioverter Defibrillator (WCD), which continuously monitors patient heart rhythms and automatically delivers defibrillation therapy when life-threatening ventricular arrhythmias are detected; digital patient engagement and clinical workflow solutions designed to improve patient adherence, support care coordination, and provide actionable clinical insights throughout the recovery process; and integrated platform generates continuous cardiac rhythm data and clinically actionable insights. Kestra Medical Technologies, Ltd. was founded in 2014 and is based in Kirkland, Washington.
Kestra Medical Technologies, Ltd. Common Stock management
10- Mr. Brian WebsterFounder, President, CEO & Director · born 1964
- Ms. Traci S. UmbergerCo-Founder, General Counsel, Chief Administrative Officer, Secretary & Director · born 1963
- Mr. Vaseem MahboobChief Financial Officer · born 1969
- Mr. Gordon TeddyChief Information Officer
- Mr. Alfred J. Ford Jr.Chief Commercial Officer · born 1971
- Mr. Neil BhalodkarVice President of Investor Relations
- Ms. Debra SchotzSenior Vice President of Marketing · born 1970
- Mr. Jeffrey LaubSenior Vice President of Operations · born 1971
- Mr. Timothy P. MoranChief Business Officer · born 1972
- Mr. R. Curtis KopfSenior Vice President of Customer Experience · born 1966